RATIONALE: A noninvasive tool allowing the detection of vulnerable atherosclerotic plaques is highly needed. By combining nanomolar affinities and fast blood clearance, nanobodies represent potential radiotracers for cardiovascular molecular imaging. Vascular cell adhesion molecule-1 (VCAM1) constitutes a relevant target for molecular imaging of atherosclerotic lesions. OBJECTIVE: We aimed to generate, radiolabel, and evaluate anti-VCAM1 nanobodies for noninvasive detection of atherosclerotic lesions. METHODS AND RESULTS: Ten anti-VCAM1 nanobodies were generated, radiolabeled with technetium-99m, and screened in vitro on mouse and human recombinant VCAM1 proteins and endothelial cells and in vivo in apolipoprotein E-deficient (ApoE(-/-)) mice. A nontargeting control nanobody was used in all experiments to demonstrate specificity. All nanobodies displayed nanomolar affinities for murine VCAM1. Flow cytometry analyses using human human umbilical vein endothelial cells indicated murine and human VCAM1 cross-reactivity for 6 of 10 nanobodies. The lead compound cAbVCAM1-5 was cross-reactive for human VCAM1 and exhibited high lesion-to-control (4.95±0.85), lesion-to-heart (8.30±1.11), and lesion-to-blood ratios (4.32±0.48) (P<0.05 versus control C57Bl/6J mice). Aortic arch atherosclerotic lesions of ApoE(-/-) mice were successfully identified by single-photon emission computed tomography imaging. (99m)Tc-cAbVCAM1-5 binding specificity was demonstrated by in vivo competition experiments. Autoradiography and immunohistochemistry further confirmed cAbVCAM1-5 uptake in VCAM1-positive lesions. CONCLUSIONS: The (99m)Tc-labeled, anti-VCAM1 nanobody cAbVCAM1-5 allowed noninvasive detection of VCAM1 expression and displayed mouse and human cross-reactivity. Therefore, this study demonstrates the potential of nanobodies as a new class of radiotracers for cardiovascular applications. The nanobody technology might evolve into an important research tool for targeted imaging of atherosclerotic lesions and has the potential for fast clinical translation.
RATIONALE: A noninvasive tool allowing the detection of vulnerable atherosclerotic plaques is highly needed. By combining nanomolar affinities and fast blood clearance, nanobodies represent potential radiotracers for cardiovascular molecular imaging. Vascular cell adhesion molecule-1 (VCAM1) constitutes a relevant target for molecular imaging of atherosclerotic lesions. OBJECTIVE: We aimed to generate, radiolabel, and evaluate anti-VCAM1 nanobodies for noninvasive detection of atherosclerotic lesions. METHODS AND RESULTS: Ten anti-VCAM1 nanobodies were generated, radiolabeled with technetium-99m, and screened in vitro on mouse and human recombinant VCAM1 proteins and endothelial cells and in vivo in apolipoprotein E-deficient (ApoE(-/-)) mice. A nontargeting control nanobody was used in all experiments to demonstrate specificity. All nanobodies displayed nanomolar affinities for murineVCAM1. Flow cytometry analyses using humanhuman umbilical vein endothelial cells indicated murine and humanVCAM1 cross-reactivity for 6 of 10 nanobodies. The lead compound cAbVCAM1-5 was cross-reactive for humanVCAM1 and exhibited high lesion-to-control (4.95±0.85), lesion-to-heart (8.30±1.11), and lesion-to-blood ratios (4.32±0.48) (P<0.05 versus control C57Bl/6J mice). Aortic arch atherosclerotic lesions of ApoE(-/-) mice were successfully identified by single-photon emission computed tomography imaging. (99m)Tc-cAbVCAM1-5 binding specificity was demonstrated by in vivo competition experiments. Autoradiography and immunohistochemistry further confirmed cAbVCAM1-5 uptake in VCAM1-positive lesions. CONCLUSIONS: The (99m)Tc-labeled, anti-VCAM1 nanobody cAbVCAM1-5 allowed noninvasive detection of VCAM1 expression and displayed mouse and human cross-reactivity. Therefore, this study demonstrates the potential of nanobodies as a new class of radiotracers for cardiovascular applications. The nanobody technology might evolve into an important research tool for targeted imaging of atherosclerotic lesions and has the potential for fast clinical translation.
Authors: Rémy T Boscacci; Friederike Pfeiffer; Kathrin Gollmer; Ana Isabel Checa Sevilla; Ana Maria Martin; Silvia Fernandez Soriano; Daniela Natale; Sarah Henrickson; Ulrich H von Andrian; Yoshinori Fukui; Mario Mellado; Urban Deutsch; Britta Engelhardt; Jens V Stein Journal: Blood Date: 2010-04-15 Impact factor: 22.113
Authors: Valentin Fuster; Pedro R Moreno; Zahi A Fayad; Roberto Corti; Juan J Badimon Journal: J Am Coll Cardiol Date: 2005-09-20 Impact factor: 24.094
Authors: Matthias Nahrendorf; Farouc A Jaffer; Kimberly A Kelly; David E Sosnovik; Elena Aikawa; Peter Libby; Ralph Weissleder Journal: Circulation Date: 2006-09-25 Impact factor: 29.690
Authors: K D O'Brien; M D Allen; T O McDonald; A Chait; J M Harlan; D Fishbein; J McCarty; M Ferguson; K Hudkins; C D Benjamin Journal: J Clin Invest Date: 1993-08 Impact factor: 14.808
Authors: Beat A Kaufmann; John M Sanders; Christopher Davis; Aris Xie; Patrick Aldred; Ian J Sarembock; Jonathan R Lindner Journal: Circulation Date: 2007-06-25 Impact factor: 29.690
Authors: K M Schweitzer; A M Dräger; P van der Valk; S F Thijsen; A Zevenbergen; A P Theijsmeijer; C E van der Schoot; M M Langenhuijsen Journal: Am J Pathol Date: 1996-01 Impact factor: 4.307
Authors: A Broisat; L M Riou; V Ardisson; D Boturyn; P Dumy; D Fagret; C Ghezzi Journal: Eur J Nucl Med Mol Imaging Date: 2007-01-12 Impact factor: 10.057
Authors: Muhammad U Ghani; Molly D Wong; Liqiang Ren; Di Wu; Bin Zheng; John X Rong; Xizeng Wu; Hong Liu Journal: Nucl Instrum Methods Phys Res A Date: 2017-02-16 Impact factor: 1.455
Authors: Ruth Röder; Jonas Helma; Tobias Preiß; Joachim O Rädler; Heinrich Leonhardt; Ernst Wagner Journal: Pharm Res Date: 2016-10-31 Impact factor: 4.200
Authors: Adriaan Verhelle; Wouter Van Overbeke; Cindy Peleman; Rebecca De Smet; Olivier Zwaenepoel; Tony Lahoutte; Jo Van Dorpe; Nick Devoogdt; Jan Gettemans Journal: Mol Imaging Biol Date: 2016-12 Impact factor: 3.488